C4 Therapeutics Inc. (CCCC)
NASDAQ · Healthcare
C4 Therapeutics Inc. Operating Income 2021–2025
C4 Therapeutics Inc. annual/quarterly operating income history and growth rate from 2021 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- C4 Therapeutics Inc. operating income for the quarter ending March 31, 2026 was -27.8 M, a 4.73% decrease year-over-year.
- C4 Therapeutics Inc. operating income for the twelve months ending March 31, 2026 was -119.9 M, a 9.25% increase year-over-year.
- C4 Therapeutics Inc. annual operating income for 2025 was -115.2 M, a 3.67% decrease from 2024.
- C4 Therapeutics Inc. annual operating income for 2024 was -119.6 M, a 13.97% decrease from 2023.
- C4 Therapeutics Inc. annual operating income for 2023 was -139.0 M, a 7.33% increase from 2022.
- C4 Therapeutics Inc. annual operating income for 2022 was -129.5 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
C4 Therapeutics Inc. Operating Income — FAQ
C4 Therapeutics Inc. (CCCC) operating income over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
What is C4 Therapeutics Inc.'s operating income?
C4 Therapeutics Inc. (CCCC) reported operating income of -$115M for fiscal 2025.
Where can I see CCCC's operating income history?
The chart and table above show C4 Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.